secwatch.observer — SEC 8-K summary
======================================

Issuer:     CRISPR Therapeutics AG (CRSP)
CIK:        0001674416
Form:       8-K
Filed at:   2023-03-27T23:59:59+00:00
Accession:  0000950170-23-009861
Event type: m_and_a
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CRISPR Therapeutics licenses CRISPR/Cas9 to Vertex for $100M upfront; eligible for $230M milestones
--------------------------------------------------------------------------------

- Vertex pays $100M upfront for non-exclusive rights to CRISPR/Cas9 for hypoimmune cell therapies in type 1 diabetes.
- CRISPR eligible for up to $230M in research and development milestones plus low-to-mid single-digit royalties.
- Vertex's existing T1D programs VX-880 and VX-264 are not included; CRISPR retains ViaCyte collaboration.
- Agreement expands existing relationship; Phase 1/2 study of VCTX211 (gene-edited stem cell therapy) is ongoing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1674416/000095017023009861/0000950170-23-009861-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1674416/000095017023009861/crsp-20230323.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-009861

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer